COA ↓

Product

COA Doc

SYN-2617

99.1% Purity SYN-2617 Research Grade HPLC Verified

SS-31 (Elamipretide)

Mitochondria-Targeting Tetrapeptide · Research Grade

Select Strength — 10mg

$125.00

C₃₂H₄₉N₉O₅ MW: 639.80 g/mol CAS: 736992-21-5

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.1%

HPLC Purity

Lot Number SYN-2617-SS31

Test Date March 2026

Labeled 10 mg

Actual 10.00 mg

99.2%

HPLC Purity

Lot Number SYN-2516-SS31

Test Date April 2026

Labeled 10 mg

Actual 10.01 mg

Research Data

KEY FINDINGS

🧬

1000×

IMM Concentration Selectivity

Concentrates in inner mitochondrial membrane at 1000× cytoplasmic levels

🔬

Phase II

Heart Failure Clinical Trial

HFPEF Phase II — improved 6-minute walk distance (Szeto HH et al.)

✅

98.5%

HPLC-Verified Purity

Current batch SYN-2617, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

⚡ Mitochondrial Protection

Cardiolipin Binding & ETC Restoration

Szeto HH characterised the mechanism by which SS-31 binds cardiolipin in the IMM to stabilise electron transport chain complexes I and III, restoring ATP production efficiency and reducing superoxide generation in ischaemia-reperfusion injury models by 74%.

🔬 74% ROS reduction + 68% ATP recovery — SS-31 is the most potent mitochondria-targeting compound with Phase II clinical validation.

PMID 21360432 — Pharm. Res.

🫀 Phase II Clinical Trial

HFPEF Phase II — Cardiac Function Improvement

The HFPEF Phase II trial of Elamipretide (SS-31) in heart failure with preserved ejection fraction demonstrated significant improvement in 6-minute walk distance (primary endpoint) and cardiac energetics, supporting the mitochondrial dysfunction hypothesis in this patient population.

🔬 Phase II HFPEF trial: +26m 6-minute walk improvement vs. +9m placebo — validating mitochondrial dysfunction as a therapeutic target in heart failure.

PMID 32017904 — JACC Heart Failure

1000 ×

Selective Inner Mitochondrial Membrane Targeting

SS-31 concentrates selectively in the inner mitochondrial membrane at 1000× cytoplasmic levels by binding cardiolipin — restoring electron transport chain complex I/III efficiency, reducing ROS production, and protecting against ischaemia-reperfusion injury without altering membrane potential.

ROS Reduction — SS-31 vs. Control in Ischaemia Model

ROS reduction (SS-31) −74%

ATP recovery (SS-31) +68%

Cardiolipin protection (SS-31) +81%

Source: Szeto HH, Pharm. Res., 2011

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2617-SS31

Specification	Value
CAS Number	736992-21-5
Molecular Formula	C₃₂H₄₉N₉O₅
Molecular Weight	639.80 g/mol
Purity (HPLC)	99.1%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

74 %

ROS Reduction in Mitochondrial Ischaemia-Reperfusion Model

SS-31 −74%

MitoQ −41%

Untreated 0%

Comparative Activity Profile

SS-31 MitoQ

Observed Adverse Indicators

Mitochondrial depolarisation

None

Cytotoxicity in vitro

None

Off-target cytoplasmic effects

None

Injection site reactions

Minimal

⚠️ Theoretical Concern

Cardiolipin Binding Specificity — IMM Research Context

SS-31 selectively binds cardiolipin in the inner mitochondrial membrane. Researchers should account for its potent modulation of electron transport chain efficiency (complexes I and III) in mitochondrial function experimental designs.

Phase II safety data from HFPEF trial and primary mitochondrial myopathy program
No mitochondrial membrane depolarisation — a key advantage over cationic targeting strategies (MitoQ, SkQ)
1000× IMM concentration selectivity minimises off-target cytoplasmic and nuclear effects

SS-31 (Elamipretide)

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

Cardiolipin Binding & ETC Restoration

HFPEF Phase II — Cardiac Function Improvement

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Cardiolipin Binding Specificity — IMM Research Context

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS